Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
06:43pm, Sunday, 21'st Sep 2025
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
05:34pm, Thursday, 18'th Sep 2025
Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?
02:31pm, Thursday, 18'th Sep 2025
Nektar Therapeutics Inc. NKTR on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 202
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
08:45am, Thursday, 18'th Sep 2025
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reporte
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
07:00am, Tuesday, 09'th Sep 2025
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
12:30pm, Monday, 08'th Sep 2025
Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.
Why Nektar Therapeutics Rippled Higher This Week
01:32pm, Friday, 05'th Sep 2025
Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.
What's Going On With Nektar Therapeutics Stock On Thursday?
02:52pm, Thursday, 04'th Sep 2025
Nektar Therapeutics Inc. NKTR stock traded higher on Thursday, with a session volume of 2.80 million versus the average volume of 1.96 million, according to data from Benzinga Pro.
Nektar Therapeutics to Participate in Two Investor Conferences in September
07:00pm, Wednesday, 03'rd Sep 2025
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
07:48pm, Friday, 08'th Aug 2025
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief R
Why Nektar Therapeutics Stock Popped 6% on Friday
06:15pm, Friday, 08'th Aug 2025
Biotech Nektar Therapeutics (NKTR 6.02%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar,
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
12:46pm, Friday, 08'th Aug 2025
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Nektar (NKTR) Q2 Revenue Falls 52%
12:51am, Friday, 08'th Aug 2025
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
06:31pm, Thursday, 07'th Aug 2025
Nektar Therapeutics (NKTR) came out with a quarterly loss of $2.95 per share versus the Zacks Consensus Estimate of a loss of $3.13. This compares to a loss of $3.75 per share a year ago.
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
04:15pm, Thursday, 07'th Aug 2025
SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securiti
